Successful restart: From 31 May to 1 June 2022, Chemspec Europe attracted 5,122 industry experts from 57 countries, of which 3,162 were trade visitors. A total of 287 exhibitors from 26 countries presented their product portfolio on a net exhibition space of 5,300 m2 at Messe Frankfurt, Germany. With topics such as sustainable innovations, regulatory compliances, circular bio-economy, green chemistry, digitalisation, and the flourishing startup scene, the 35th International Exhibition for Fine and Speciality Chemicals highlighted insights of current and future developments within the industry.
$50m for London CHARM Therapeutics for deep minded folding expertise
Latest NewsCHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology.
Biotalys first proteinbased biocontrol shows up in vineyards
Latest NewsBased on data from the latest trials in grapes across vineyards in diverse climates throughout California and New York, Biotalys’ biocontrol product Evoca provided superior preventative control of Botrytis bunch rot in grapevines compared to chemical standard. Approval is estimated within this year.
Andera Partners co-leads $118m Series B of Mineralys thx (USA)
Latest NewsAndera Partners, Paris based European private equity player, announced on Wednesday that, together with RA Capital Management, it is leading an oversubscribed and up-sized $118m Series B financing for Mineralys Therapeutics, Inc., Philadelphia (USA), a private, clinical-stage biopharmaceutical company developing novel therapy for the treatment of hypertension.
Chemspec Europe 2022 wrapped up with high-level networking and learning opportunities
Sponsored PublicationsSuccessful restart: From 31 May to 1 June 2022, Chemspec Europe attracted 5,122 industry experts from 57 countries, of which 3,162 were trade visitors. A total of 287 exhibitors from 26 countries presented their product portfolio on a net exhibition space of 5,300 m2 at Messe Frankfurt, Germany. With topics such as sustainable innovations, regulatory compliances, circular bio-economy, green chemistry, digitalisation, and the flourishing startup scene, the 35th International Exhibition for Fine and Speciality Chemicals highlighted insights of current and future developments within the industry.
From waste to sugar – demonstration plant opens in Wales
Latest NewsThe South Wales-based demonstration plant "VAMOS" that generates industrial biotechnology sugars and other recycled material streams from the paper and card in mixed household waste has come online these days. The products will be used in the production of several high-performance bio-based materials.
International Vaccine Institute – IVI – will locate its European office in Stockholm
Latest NewsThe International Vaccine Institute, IVI, which is associated with the WHO and UN, will locate its European office in Stockholm. To date, the institute is only located in the host country of South Korea.
Abliva decides on a SEK200m financing to fund Phase 2/3 study
Latest NewsThe financing (around €19m) shall fully fund the commencement of a potentially pivotal/registrational Phase 2/3 study for KL1333 and its progression to the outcome of a key interim analysis.
Transine Therapeutics Ltd closes £13.7m seed financing
Latest NewsTransine Therapeutics Ltd has added £4.6m from lead investor Epidarex Capital and the Dementia Discovery Fund (DDF) to its £9.1m seed funding led by Takeda Ventures and DDF.
MGI turns a new page in the human genome era with ultra-high throughout DNBSEQ-T7 sequencer*
Sponsored PublicationsAmidst the rapid evolution of DNA sequencing technologies in past years, the industry has been working tirelessly to make genomics more accessible. Since the Human Genome Project, which saw scientists from six countries coming together to map the first human genome at nearly $3 billion over 13 years, the cost of whole-genome sequencing has fallen to less than $1,000 today. Yet, the quest to produce larger amounts of short- and long-read data in a shorter span of time and at an even lower cost continues.
Orphan drug developer Minoryx raises €51m
Latest NewsMinoryx Therapeutics SL has closed a €51m financing, including Series C equity financing and complementary bank debt to commercialise X-ALD drug leriglitazone.